Cediranib
- Generic Name
- Cediranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27FN4O3
- CAS Number
- 288383-20-0
- Unique Ingredient Identifier
- NQU9IPY4K9
- Background
The novel indole-ether quinazoline Cediranib is a highly potent (IC < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
- Indication
For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
- Conditions
- Anatomic Stage IIIA Breast Cancer AJCC v8Germline BRCA1 Gene MutationGermline BRCA2 Gene MutationHER2/Neu NegativeMetastatic Breast CarcinomaPrognostic Stage III Breast Cancer AJCC v8Advanced Breast CarcinomaAnatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04090567
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 90
- Registration Number
- NCT03851614
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
WIRE - Novel Treatments in Renal Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- CCTU- Cancer Theme
- Target Recruit Count
- 60
- Registration Number
- NCT03741426
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧Beatson Institute for Cancer Research, Glasgow, United Kingdom
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
- Conditions
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 288
- Registration Number
- NCT03660826
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
🇺🇸Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
- Conditions
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- University of Manchester
- Target Recruit Count
- 124
- Registration Number
- NCT03570437
- Locations
- 🇬🇧
Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, United Kingdom
🇬🇧Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom
🇬🇧Bristol Haematology & Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 531
- Registration Number
- NCT03334617
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2019-05-14
- Target Recruit Count
- 100
- Registration Number
- NCT03314740
- Locations
- 🇮🇹
Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹Istituto Oncologico Veneto (IOV), Padova, PD, Italy
🇮🇹Arcispedale Santa Maria Nuova, Reggio Emilia, RE, Italy
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- University College, London
- Target Recruit Count
- 330
- Registration Number
- NCT03278717
- Locations
- 🇦🇺
Calvary Mater Hospital, Sydney, New South Wales, Australia
🇦🇺Campbelltown Hospital, Sydney, New South Wales, Australia
🇦🇺Prince of Wales Hospital, Sydney, New South Wales, Australia
Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 139
- Registration Number
- NCT03117933
- Locations
- 🇬🇧
Royal Marsden Chelsea & Sutton, London, United Kingdom
🇬🇧The Christie, Manchester, United Kingdom
🇬🇧Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT02974621
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.